Literature DB >> 32366817

A human monoclonal antibody blocking SARS-CoV-2 infection.

Chunyan Wang1, Wentao Li1, Dubravka Drabek2,3, Nisreen M A Okba4, Rien van Haperen2,3, Albert D M E Osterhaus5, Frank J M van Kuppeveld1, Bart L Haagmans4, Frank Grosveld2,3, Berend-Jan Bosch6.   

Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in cell culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32366817      PMCID： PMC7198537          DOI： 10.1038/s41467-020-16256-y

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


  391 in total

1.  Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.

Authors:  Jiandong Huo; Audrey Le Bas; Reinis R Ruza; Helen M E Duyvesteyn; Halina Mikolajek; Tomas Malinauskas; Tiong Kit Tan; Pramila Rijal; Maud Dumoux; Philip N Ward; Jingshan Ren; Daming Zhou; Peter J Harrison; Miriam Weckener; Daniel K Clare; Vinod K Vogirala; Julika Radecke; Lucile Moynié; Yuguang Zhao; Javier Gilbert-Jaramillo; Michael L Knight; Julia A Tree; Karen R Buttigieg; Naomi Coombes; Michael J Elmore; Miles W Carroll; Loic Carrique; Pranav N M Shah; William James; Alain R Townsend; David I Stuart; Raymond J Owens; James H Naismith
Journal:  Nat Struct Mol Biol       Date:  2020-07-13       Impact factor: 15.369

Review 2.  Biological characteristics and biomarkers of novel SARS-CoV-2 facilitated rapid development and implementation of diagnostic tools and surveillance measures.

Authors:  Gajanan Sampatrao Ghodake; Surendra Krushna Shinde; Avinash Ashok Kadam; Rijuta Ganesh Saratale; Ganesh Dattatraya Saratale; Asad Syed; Abdallah M Elgorban; Najat Marraiki; Dae-Young Kim
Journal:  Biosens Bioelectron       Date:  2021-01-04       Impact factor: 10.618

3.  A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.

Authors:  Chunyan Wang; Rien van Haperen; Javier Gutiérrez-Álvarez; Wentao Li; Nisreen M A Okba; Irina Albulescu; Ivy Widjaja; Brenda van Dieren; Raul Fernandez-Delgado; Isabel Sola; Daniel L Hurdiss; Olalekan Daramola; Frank Grosveld; Frank J M van Kuppeveld; Bart L Haagmans; Luis Enjuanes; Dubravka Drabek; Berend-Jan Bosch
Journal:  Nat Commun       Date:  2021-03-17       Impact factor: 14.919

Review 4.  COVID-19: The Emerging Immunopathological Determinants for Recovery or Death.

Authors:  Tanveer Ahmad; Rituparna Chaudhuri; Mohan C Joshi; Ahmad Almatroudi; Arshad Husain Rahmani; Syed Mansoor Ali
Journal:  Front Microbiol       Date:  2020-12-01       Impact factor: 5.640

5.  Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes.

Authors:  Tongqing Zhou; I-Ting Teng; Adam S Olia; Gabriele Cerutti; Jason Gorman; Alexandra Nazzari; Wei Shi; Yaroslav Tsybovsky; Lingshu Wang; Shuishu Wang; Baoshan Zhang; Yi Zhang; Phinikoula S Katsamba; Yuliya Petrova; Bailey B Banach; Ahmed S Fahad; Lihong Liu; Sheila N Lopez Acevedo; Bharat Madan; Matheus Olivera de Souza; Xiaoli Pan; Pengfei Wang; Jacy R Wolfe; Michael Yin; David D Ho; Emily Phung; Anthony DiPiazza; Lauren Chang; Olubukula Abiona; Kizzmekia S Corbett; Brandon J DeKosky; Barney S Graham; John R Mascola; John Misasi; Tracy Ruckwardt; Nancy J Sullivan; Lawrence Shapiro; Peter D Kwong
Journal:  SSRN       Date:  2020-07-21

6.  Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization.

Authors:  Eric Salazar; Suresh V Kuchipudi; Paul A Christensen; Todd Eagar; Xin Yi; Picheng Zhao; Zhicheng Jin; S Wesley Long; Randall J Olsen; Jian Chen; Brian Castillo; Christopher Leveque; Dalton Towers; Jason Lavinder; Jimmy Gollihar; Jose Cardona; Gregory Ippolito; Ruth Nissly; Ian Bird; Denver Greenawalt; Randall M Rossi; Abhinay Gontu; Sreenidhi Srinivasan; Indira Poojary; Isabella M Cattadori; Peter J Hudson; Nicole M Josleyn; Laura Prugar; Kathleen Huie; Andrew Herbert; David W Bernard; John M Dye; Vivek Kapur; James M Musser
Journal:  J Clin Invest       Date:  2020-12-01       Impact factor: 14.808

7.  Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.

Authors:  Dora Pinto; Young-Jun Park; Martina Beltramello; Alexandra C Walls; M Alejandra Tortorici; Siro Bianchi; Stefano Jaconi; Katja Culap; Fabrizia Zatta; Anna De Marco; Alessia Peter; Barbara Guarino; Roberto Spreafico; Elisabetta Cameroni; James Brett Case; Rita E Chen; Colin Havenar-Daughton; Gyorgy Snell; Amalio Telenti; Herbert W Virgin; Antonio Lanzavecchia; Michael S Diamond; Katja Fink; David Veesler; Davide Corti
Journal:  Nature       Date:  2020-05-18       Impact factor: 49.962

8.  Recombinant SARS-CoV-2 S Protein Binds to Glycans of the Lactosamine Family in vitro.

Authors:  Alexandr B Ryzhikov; Galina S Onkhonova; Ilnaz R Imatdinov; Elena V Gavrilova; Rinat A Maksyutov; Elena A Gordeeva; Galina V Pazynina; Ivan M Ryzhov; Nadezhda V Shilova; Nicolai V Bovin
Journal:  Biochemistry (Mosc)       Date:  2021-03       Impact factor: 2.487

9.  Spike-specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-convalescent individuals.

Authors:  Jian Zhang; Qian Wu; Ziyan Liu; Qijie Wang; Jiajing Wu; Yabin Hu; Tingting Bai; Ting Xie; Mincheng Huang; Tiantian Wu; Danhong Peng; Weijin Huang; Kun Jin; Ling Niu; Wangyuan Guo; Dixian Luo; Dongzhu Lei; Zhijian Wu; Guicheng Li; Renbin Huang; Yingbiao Lin; Xiangping Xie; Shuangyan He; Yunfan Deng; Jianghua Liu; Weilang Li; Zhongyi Lu; Haifu Chen; Ting Zeng; Qingting Luo; Yi-Ping Li; Youchun Wang; Wenpei Liu; Xiaowang Qu
Journal:  Nat Microbiol       Date:  2020-11-16       Impact factor: 17.745

10.  Designed proteins assemble antibodies into modular nanocages.

Authors:  Robby Divine; Ha V Dang; George Ueda; Jorge A Fallas; Ivan Vulovic; William Sheffler; Shally Saini; Yan Ting Zhao; Infencia Xavier Raj; Peter A Morawski; Madeleine F Jennewein; Leah J Homad; Yu-Hsin Wan; Marti R Tooley; Franziska Seeger; Ali Etemadi; Mitchell L Fahning; James Lazarovits; Alex Roederer; Alexandra C Walls; Lance Stewart; Mohammadali Mazloomi; Neil P King; Daniel J Campbell; Andrew T McGuire; Leonidas Stamatatos; Hannele Ruohola-Baker; Julie Mathieu; David Veesler; David Baker
Journal:  Science       Date:  2021-04-02       Impact factor: 47.728
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.